Nucleic Acid, Nucleoside, or Nucleotide
Judo Bio Launches with $100M to Pioneer Kidney-Targeted siRNA Therapies
Judo Bio, siRNA therapies, kidney diseases, oligonucleotide medicines, STRIKE platform, megalin-STRIKERS, renal diseases, genetic medicines.
Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations
Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
Senators Wyden and Brown Call for FTC Investigation into PBM “Co-Manufacturing” Practices
PBM reforms, FTC investigation, co-manufacturing, pharmacy benefit managers, drug costs, competition, healthcare industry
Senators Wyden and Brown Urge FTC to Expand Investigation into PBMs’ Anti-Competitive Practices
Pharmacy Benefit Managers (PBMs), Anti-Competitive Practices, FTC Investigation, Co-Manufacturing Agreements, Drug Prices, Healthcare Reform
Moderna Faces Second Consecutive Marketing Breach for Spikevax Vaccine
Moderna, Spikevax, Marketing Breach, COVID-19 Vaccine, Regulatory Compliance
Cigna Challenges FTC’s Report on Pharmacy Benefit Managers, Alleging Unconstitutional Actions and Misleading Claims
Cigna, FTC, Pharmacy Benefit Managers (PBMs), Express Scripts, Unconstitutional Report, Misleading Claims, Drug Prices, Healthcare System
Novo Nordisk and NanoVation Collaborate on $600M Genetic Medicine Deal for Rare and Cardiometabolic Diseases
Novo Nordisk, NanoVation, genetic medicine, lipid nanoparticle technology, cardiometabolic diseases, rare diseases, RNA delivery, base-editing therapies
Cigna’s Express Scripts Files Lawsuit Against FTC Over Allegedly Biased PBM Report
Express Scripts, FTC, PBM Report, Lawsuit, Biased, Erroneous, Drug Prices, Healthcare
GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results
GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.